AI Article Synopsis

  • The study aimed to assess the effectiveness and safety of platinum/vinorelbine as a treatment option beyond second-line therapy for advanced non-small cell lung cancer (NSCLC).
  • Out of 35 patients, the treatment showed a 22.9% response rate, with better outcomes for those who had previously responded to chemotherapy, while median progression-free and overall survival were reported at 4 and 10 months, respectively.
  • Neutropenia was the main serious side effect observed, suggesting that while platinum/vinorelbine can be a viable treatment option, monitoring for this adverse effect is crucial.

Article Abstract

Purpose: There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-line treatment.

Materials And Methods: We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. The primary end point was the response rate, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.

Results: Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients [0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressive disease, 14 patients [40.0%]). A significantly higher response rate was observed for patients who had responded to previous chemotherapy than for those who did not (34.8% [8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS than patients with poor performance status and smokers (14 months vs. 4 months, p=0.02; 18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade 3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles.

Conclusion: Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614189PMC
http://dx.doi.org/10.4143/crt.2014.316DOI Listing

Publication Analysis

Top Keywords

months months
16
patients
12
response rate
12
months
12
efficacy safety
8
safety platinum/vinorelbine
8
platinum/vinorelbine second-line
8
second-line chemotherapy
8
advanced non-small
8
non-small cell
8

Similar Publications

Background And Importance: Traumatic intracranial hemorrhage (tICH) after mild traumatic brain injury (mTBI) is not uncommon in the elderly. Often, these patients are admitted to the hospital for observation. The necessity of admission in the absence of clinically important intracranial injuries is however unclear.

View Article and Find Full Text PDF
Article Synopsis
  • The negative symptoms of schizophrenia, like lack of emotion and motivation, are hard to treat and significantly impact daily functioning.
  • This review highlights current research on treatment options for these symptoms, categorizing them into different types and evaluating various assessment scales.
  • Although no treatments are conclusively proven as the best for these symptoms, some off-label and investigational medications show promise, including cariprazine and memantine, and further research is needed to explore new therapeutic possibilities.
View Article and Find Full Text PDF

Objectives: To describe the clinical profile and compare the long-term outcomes of patients with S-PAN treated with various treatment regimens at our centre in the last 2 decades.

Methods: Data regarding clinical presentation, treatment allocation, relapses and outcomes of patients fulfilling American College of Rheumatology (ACR) 1990 criteria for PAN in the last 2 decades were recorded from electronic medical records. Relapse-free survival and predictors were analysed using KM survival statistics and regression analysis.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the feasibility of an online cognitive behavioral therapy (CBT) program for patients recovering from extremity fractures compared to usual care.
  • Despite enrolling 94 participants, recruitment showed a "yellow light," indicating some success but needing improvements.
  • Compliance with the CBT program was low, as only 60% completed all modules, leading to a "red light," suggesting significant changes are necessary before a larger trial can proceed.
View Article and Find Full Text PDF

Superficial acral fibromyxoma on the palm: a case report.

J Med Case Rep

January 2025

Department of Clinical Medicine, Jining Medical University, Jining, China.

Background: Superficial acral fibromyxoma is a noncancerous, benign tumor of soft tissue with an unidentified origin. Occurrences of abnormalities on the palm are less frequently documented.

Case Report Presentation: A 47-year-old East Asian woman presented with a palm tumor on her left knuckle that had been present for 4 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!